JP2015514757A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015514757A5 JP2015514757A5 JP2015506953A JP2015506953A JP2015514757A5 JP 2015514757 A5 JP2015514757 A5 JP 2015514757A5 JP 2015506953 A JP2015506953 A JP 2015506953A JP 2015506953 A JP2015506953 A JP 2015506953A JP 2015514757 A5 JP2015514757 A5 JP 2015514757A5
- Authority
- JP
- Japan
- Prior art keywords
- paa
- dose
- pagn
- target range
- prodrug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940002612 prodrug Drugs 0.000 claims 25
- 239000000651 prodrug Substances 0.000 claims 25
- 238000000034 method Methods 0.000 claims 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000014759 maintenance of location Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 230000009286 beneficial effect Effects 0.000 claims 2
- 238000005259 measurement Methods 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 201000000523 end stage renal failure Diseases 0.000 claims 1
- ZSDBFLMJVAGKOU-UHFFFAOYSA-N glycerol phenylbutyrate Chemical compound C=1C=CC=CC=1CCCC(=O)OCC(OC(=O)CCCC=1C=CC=CC=1)COC(=O)CCCC1=CC=CC=C1 ZSDBFLMJVAGKOU-UHFFFAOYSA-N 0.000 claims 1
- 229960002815 glycerol phenylbutyrate Drugs 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000007056 sickle cell anemia Diseases 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636256P | 2012-04-20 | 2012-04-20 | |
| US61/636,256 | 2012-04-20 | ||
| PCT/US2012/054673 WO2013158145A1 (en) | 2012-04-20 | 2012-09-11 | Methods of therapeutic monitoring of phenylacetic acid prodrugs |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017204831A Division JP6637941B2 (ja) | 2012-04-20 | 2017-10-24 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015514757A JP2015514757A (ja) | 2015-05-21 |
| JP2015514757A5 true JP2015514757A5 (enExample) | 2015-11-05 |
| JP6234436B2 JP6234436B2 (ja) | 2017-11-22 |
Family
ID=49380684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015506953A Active JP6234436B2 (ja) | 2012-04-20 | 2012-09-11 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
| JP2017204831A Active JP6637941B2 (ja) | 2012-04-20 | 2017-10-24 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
| JP2019149843A Pending JP2019219413A (ja) | 2012-04-20 | 2019-08-19 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017204831A Active JP6637941B2 (ja) | 2012-04-20 | 2017-10-24 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
| JP2019149843A Pending JP2019219413A (ja) | 2012-04-20 | 2019-08-19 | フェニル酢酸プロドラッグの治療モニタリングの方法 |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US9561197B2 (enExample) |
| EP (2) | EP2846791B1 (enExample) |
| JP (3) | JP6234436B2 (enExample) |
| KR (2) | KR102264579B1 (enExample) |
| CN (3) | CN113995743A (enExample) |
| AU (3) | AU2012377389A1 (enExample) |
| BR (1) | BR112014026138A2 (enExample) |
| CL (2) | CL2014002807A1 (enExample) |
| CY (1) | CY1118838T1 (enExample) |
| DK (1) | DK2846791T3 (enExample) |
| EC (1) | ECSP14024561A (enExample) |
| ES (2) | ES2623470T3 (enExample) |
| HR (1) | HRP20170651T1 (enExample) |
| HU (1) | HUE032726T2 (enExample) |
| IL (2) | IL235127A (enExample) |
| LT (1) | LT2846791T (enExample) |
| MX (1) | MX365302B (enExample) |
| PL (1) | PL2846791T3 (enExample) |
| PT (1) | PT2846791T (enExample) |
| RS (1) | RS55870B1 (enExample) |
| SG (2) | SG10201608749UA (enExample) |
| SI (1) | SI2846791T1 (enExample) |
| SM (1) | SMT201700219T1 (enExample) |
| WO (1) | WO2013158145A1 (enExample) |
| ZA (1) | ZA201407597B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| BR112014026138A2 (pt) | 2012-04-20 | 2017-06-27 | Hyperion Therapeutics Inc | métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético |
| HUE036133T2 (hu) | 2012-11-21 | 2018-06-28 | Horizon Therapeutics Llc | Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére |
| PL2986325T3 (pl) | 2013-10-14 | 2020-03-31 | Immedica Pharma Ab | Sposoby leczenia zaburzenia cyklu mocznikowego |
| ES2748294T3 (es) * | 2014-06-04 | 2020-03-16 | Immedica Pharma Ab | Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre |
| US9914692B2 (en) | 2016-05-25 | 2018-03-13 | Horizon Therapeutics, Llc | Procedure for the preparation of 4-phenyl butyrate and uses thereof |
| US20190076383A1 (en) * | 2017-09-08 | 2019-03-14 | Horizon Therapeutics, Llc | Methods for treating urea cycle disorders |
| US10668040B2 (en) | 2017-09-11 | 2020-06-02 | Horizon Therapeutics, Llc | Treatment of urea cycle disorders in neonates and infants |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4284647A (en) | 1980-03-31 | 1981-08-18 | The Johns Hopkins University | Process for waste nitrogen removal |
| US4457942A (en) | 1982-08-20 | 1984-07-03 | Brusilow Saul W | Process for waste nitrogen removal |
| US5635532A (en) | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
| US5879657A (en) | 1993-03-30 | 1999-03-09 | The Dupont Merck Pharmaceutical Company | Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders |
| WO1996024571A1 (en) | 1995-02-07 | 1996-08-15 | Brusilow Saul W | Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders |
| US6219567B1 (en) | 1999-06-21 | 2001-04-17 | Cardiox Corporation | Monitoring of total ammoniacal concentration in blood |
| US20030195255A1 (en) | 2002-04-12 | 2003-10-16 | Summar Marshall L. | Method for treating hepatic encephalopathies |
| US20040229948A1 (en) | 2002-04-12 | 2004-11-18 | Summar Marshall L. | Method for preventing hepatic encephalopathic episodes |
| US20050273359A1 (en) | 2004-06-03 | 2005-12-08 | Young David E | System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure |
| PT2319581E (pt) | 2004-11-26 | 2015-06-30 | Ucl Business Plc | Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática |
| US20060135612A1 (en) | 2004-12-17 | 2006-06-22 | U.S. Department Of Veterans Affairs | Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent |
| US20070004805A1 (en) | 2005-07-01 | 2007-01-04 | Navinta Llc | Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate |
| US20100016207A1 (en) | 2005-11-10 | 2010-01-21 | Wurtman Richard J | Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid |
| US8094521B2 (en) | 2007-02-28 | 2012-01-10 | Nightingale Products LLC | Caregiver personal alert device |
| GB2451259B (en) * | 2007-07-25 | 2011-07-20 | Gp Acoustics | Loudspeaker |
| US9078864B2 (en) | 2008-01-08 | 2015-07-14 | Akthelia Pharmaceuticals | Agonists for antimicrobial peptide systems |
| GB2465250B (en) * | 2008-08-29 | 2011-01-26 | Ucyclyd Pharma Inc | Dosing and monitoring patients on nitrogen-scavenging drugs |
| WO2009134460A1 (en) * | 2008-04-29 | 2009-11-05 | Hyperion Therapeutics | Methods of treatment using ammonia-scavenging drugs |
| JP5577341B2 (ja) * | 2008-08-29 | 2014-08-20 | ハイペリオン セラピューティクス， インコーポレイテッド | アンモニア捕捉薬を使用する処置方法 |
| CN102481269B (zh) * | 2009-05-11 | 2015-10-07 | 博格有限责任公司 | 包含辅酶q10的药物组合物及其制备方法 |
| EP2954780A1 (en) | 2009-07-24 | 2015-12-16 | Baylor College Of Medicine | Methods of modulation of branched chain acids and uses thereof |
| JP6049619B2 (ja) | 2010-08-31 | 2016-12-21 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用 |
| EP3263102A1 (en) | 2011-09-30 | 2018-01-03 | Horizon Therapeutics, LLC | Methods of therapeutic monitoring of nitrogen scavenging drugs |
| BR112014026138A2 (pt) * | 2012-04-20 | 2017-06-27 | Hyperion Therapeutics Inc | métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético |
| HUE036133T2 (hu) | 2012-11-21 | 2018-06-28 | Horizon Therapeutics Llc | Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére |
-
2012
- 2012-09-11 BR BR112014026138A patent/BR112014026138A2/pt not_active Application Discontinuation
- 2012-09-11 SI SI201230933A patent/SI2846791T1/sl unknown
- 2012-09-11 KR KR1020197029026A patent/KR102264579B1/ko active Active
- 2012-09-11 RS RS20170421A patent/RS55870B1/sr unknown
- 2012-09-11 SG SG10201608749UA patent/SG10201608749UA/en unknown
- 2012-09-11 KR KR1020147032114A patent/KR20150013170A/ko not_active Withdrawn
- 2012-09-11 CN CN202111191403.5A patent/CN113995743A/zh active Pending
- 2012-09-11 LT LTEP12874745.8T patent/LT2846791T/lt unknown
- 2012-09-11 US US13/610,580 patent/US9561197B2/en active Active
- 2012-09-11 PL PL12874745T patent/PL2846791T3/pl unknown
- 2012-09-11 AU AU2012377389A patent/AU2012377389A1/en not_active Abandoned
- 2012-09-11 EP EP12874745.8A patent/EP2846791B1/en active Active
- 2012-09-11 SM SM20170219T patent/SMT201700219T1/it unknown
- 2012-09-11 PT PT128747458T patent/PT2846791T/pt unknown
- 2012-09-11 SG SG11201406745VA patent/SG11201406745VA/en unknown
- 2012-09-11 CN CN201280074143.6A patent/CN104540507A/zh active Pending
- 2012-09-11 ES ES12874745.8T patent/ES2623470T3/es active Active
- 2012-09-11 HR HRP20170651TT patent/HRP20170651T1/hr unknown
- 2012-09-11 ES ES17154858T patent/ES2807951T3/es active Active
- 2012-09-11 HU HUE12874745A patent/HUE032726T2/en unknown
- 2012-09-11 EP EP17154858.9A patent/EP3222275B1/en active Active
- 2012-09-11 DK DK12874745.8T patent/DK2846791T3/en active
- 2012-09-11 MX MX2014012694A patent/MX365302B/es active IP Right Grant
- 2012-09-11 CN CN202010449455.7A patent/CN111991383A/zh active Pending
- 2012-09-11 WO PCT/US2012/054673 patent/WO2013158145A1/en not_active Ceased
- 2012-09-11 JP JP2015506953A patent/JP6234436B2/ja active Active
-
2014
- 2014-10-17 CL CL2014002807A patent/CL2014002807A1/es unknown
- 2014-10-19 IL IL235127A patent/IL235127A/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07597A patent/ZA201407597B/en unknown
- 2014-10-27 EC ECIEPI201424561A patent/ECSP14024561A/es unknown
-
2017
- 2017-01-10 US US15/402,780 patent/US20170266143A1/en not_active Abandoned
- 2017-04-20 CY CY20171100449T patent/CY1118838T1/el unknown
- 2017-05-30 CL CL2017001375A patent/CL2017001375A1/es unknown
- 2017-08-25 US US15/687,136 patent/US20180015058A1/en not_active Abandoned
- 2017-10-24 JP JP2017204831A patent/JP6637941B2/ja active Active
- 2017-11-26 IL IL255918A patent/IL255918B/en active IP Right Grant
-
2018
- 2018-01-09 AU AU2018200163A patent/AU2018200163B2/en active Active
- 2018-05-15 US US15/980,431 patent/US20180263938A1/en not_active Abandoned
-
2019
- 2019-03-15 AU AU2019201811A patent/AU2019201811B2/en active Active
- 2019-08-19 JP JP2019149843A patent/JP2019219413A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ725006A (en) | Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns | |
| NZ708526A (en) | Novel rock inhibitors | |
| JP2011173928A5 (enExample) | ||
| MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| JP2016523862A5 (enExample) | ||
| JP2017503820A5 (enExample) | ||
| WO2013052699A3 (en) | Novel quinoxaline inhibitors of pi3k | |
| TN2011000217A1 (en) | Pirfenidone treatment for patients with atypical liver fuction | |
| EA033113B1 (ru) | Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта | |
| JP2013067645A5 (enExample) | ||
| NZ711179A (en) | Oral formulations of deferasirox | |
| BR112015010396A2 (pt) | terapia de combinação | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| JP2017513809A5 (enExample) | ||
| JP2014513065A5 (enExample) | ||
| JP2012502103A5 (enExample) | ||
| RU2016117729A (ru) | Терапия рака путем таргетинга покоящихся раковых клеток | |
| Besse et al. | A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer | |
| JP2016512247A5 (enExample) | ||
| FI3352735T3 (fi) | Pitkitetysti vapauttavia olantsapiiniformulaatioita | |
| JP2016505050A5 (enExample) | ||
| JP2015504094A5 (enExample) | ||
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| Soliman et al. | Miktoarm star micelles containing curcumin reduce cell viability of sensitized glioblastoma | |
| Santesteban | Ethambutol/isoniazid/pyrazinamide/rifampicin |